PT3672962T - Compostos de morfolinilpiridona - Google Patents

Compostos de morfolinilpiridona

Info

Publication number
PT3672962T
PT3672962T PT187591052T PT18759105T PT3672962T PT 3672962 T PT3672962 T PT 3672962T PT 187591052 T PT187591052 T PT 187591052T PT 18759105 T PT18759105 T PT 18759105T PT 3672962 T PT3672962 T PT 3672962T
Authority
PT
Portugal
Prior art keywords
morpholinylpyridone
compounds
morpholinylpyridone compounds
Prior art date
Application number
PT187591052T
Other languages
English (en)
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of PT3672962T publication Critical patent/PT3672962T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
PT187591052T 2017-08-23 2018-08-23 Compostos de morfolinilpiridona PT3672962T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23

Publications (1)

Publication Number Publication Date
PT3672962T true PT3672962T (pt) 2022-04-12

Family

ID=59686888

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187591052T PT3672962T (pt) 2017-08-23 2018-08-23 Compostos de morfolinilpiridona

Country Status (19)

Country Link
US (2) US11560374B2 (pt)
EP (2) EP3672962B1 (pt)
JP (2) JP7199736B2 (pt)
KR (1) KR20200044025A (pt)
CN (3) CN116444510A (pt)
AU (2) AU2018320419B2 (pt)
CA (1) CA3073142A1 (pt)
DK (1) DK3672962T3 (pt)
ES (1) ES2910157T3 (pt)
HR (1) HRP20220497T1 (pt)
HU (1) HUE058661T2 (pt)
IL (3) IL302077A (pt)
LT (1) LT3672962T (pt)
PL (1) PL3672962T3 (pt)
PT (1) PT3672962T (pt)
RS (1) RS63109B1 (pt)
SI (1) SI3672962T1 (pt)
TW (2) TW202348601A (pt)
WO (1) WO2019038390A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251165A1 (en) 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
EP2655375B1 (fr) * 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) * 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3042900B1 (en) * 2013-08-29 2020-09-23 Fujifilm Corporation Novel morpholine derivative or salt thereof
EP3094325B1 (en) 2014-01-14 2021-10-13 Takeda Pharmaceutical Company Limited Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2017009751A1 (en) * 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN108884067B (zh) * 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
WO2017140841A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Also Published As

Publication number Publication date
CA3073142A1 (en) 2019-02-28
PL3672962T3 (pl) 2022-05-02
WO2019038390A1 (en) 2019-02-28
JP7199736B2 (ja) 2023-01-06
RU2020110506A (ru) 2021-09-23
AU2018320419A1 (en) 2020-04-09
IL292489A (en) 2022-06-01
AU2018320419B2 (en) 2023-09-28
JP2023021268A (ja) 2023-02-10
TW201912161A (zh) 2019-04-01
IL292489B1 (en) 2023-05-01
CN111108102B (zh) 2023-04-28
CN111108102A (zh) 2020-05-05
JP2020531485A (ja) 2020-11-05
CN116462674A (zh) 2023-07-21
ES2910157T3 (es) 2022-05-11
IL272815B (en) 2022-06-01
RU2020110506A3 (pt) 2022-02-22
SI3672962T1 (sl) 2022-06-30
IL292489B2 (en) 2023-09-01
HUE058661T2 (hu) 2022-09-28
EP3672962A1 (en) 2020-07-01
TWI803511B (zh) 2023-06-01
KR20200044025A (ko) 2020-04-28
TW202348601A (zh) 2023-12-16
US11560374B2 (en) 2023-01-24
EP3672962B1 (en) 2022-01-26
IL302077A (en) 2023-06-01
CN116444510A (zh) 2023-07-18
US20200361922A1 (en) 2020-11-19
HRP20220497T1 (hr) 2022-05-27
EP4056569A1 (en) 2022-09-14
IL272815A (en) 2020-04-30
LT3672962T (lt) 2022-05-10
AU2023285995A1 (en) 2024-01-25
RS63109B1 (sr) 2022-04-29
US20230234949A1 (en) 2023-07-27
DK3672962T3 (da) 2022-05-02

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201700814D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201706162D0 (en) Compounds
IL292489B2 (en) Morpholinylpyridone compounds
GB201715786D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201720064D0 (en) Compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds
GB201716688D0 (en) Compounds
GB201716392D0 (en) Compounds